|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:address
|
1 Casper Street, Danbury, CT 06810, USA
|
|
gptkbp:AfrezzaIndication
|
gptkb:diabetes_mellitus
|
|
gptkbp:CEO
|
gptkb:Michael_Castagna
|
|
gptkbp:collaboratedWith
|
gptkb:United_Therapeutics
NellOne Therapeutics
Receptor Life Sciences
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:FDAApproved
|
Afrezza (2014)
|
|
gptkbp:focusesOn
|
inhalable therapeutics
|
|
gptkbp:foundedBy
|
gptkb:Alfred_E._Mann
|
|
gptkbp:foundedYear
|
1991
|
|
gptkbp:headquartersLocation
|
gptkb:Danbury,_Connecticut,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MannKind Corporation
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableProduct
|
gptkb:Afrezza
|
|
gptkbp:numberOfEmployees
|
~300
|
|
gptkbp:product
|
gptkb:Afrezza
Technosphere Insulin
V-Go (licensed)
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:researchInterest
|
endocrine diseases
orphan lung diseases
pulmonary drug delivery
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:Russell_2000
|
|
gptkbp:stockSymbol
|
MNKD
|
|
gptkbp:subsidiary
|
none
|
|
gptkbp:tradedOn
|
NASDAQ:MNKD
|
|
gptkbp:website
|
https://www.mannkindcorp.com/
|
|
gptkbp:bfsParent
|
gptkb:Afrezza
gptkb:Al_Mann
|
|
gptkbp:bfsLayer
|
7
|